CDER Offices and Divisions
Learn more about the offices and divisions in FDA's Center for Drug Evaluation and Research (CDER)
Offices
Office of the Center Director
Office of Communications
Office of Compliance
Office of Executive Programs
Office of Generic Drugs
Office of Management
Office of Medical Policy
Office of New Drugs
- Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN)
- Division of Cardiology and Nephrology (DCN)
- Division of Diabetes, Lipid Disorders and Obesity (DDLO)
- Division of General Endocrinology (DGE)
- Division of Division of Non-malignant Hematology (DNH)
- Division of Pharm/Tox for Cardiology, Hematology, Endocrinology and Nephrology (DPT-CHEN)
- Office of Drug Evaluation Sciences
- Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN)
- Division of Biomedical Informatics, Research, and Biomarker Development (DBIRBD)
- Digital Health Technology
- Drug Trials Snapshot
- Office of Immunology and Inflammation (OII)
- Division of Dermatology and Dentistry (DDD)
- Division of Gastroenterology (DG)
- Division of Hepatology and Nutrition (DHN)
- Division of Pulmonology, Allergy and Critical Care (DPACC)
- Division of Rheumatology and Transplant Medicine (DRTM)
- Division of Pharm/Tox for Immunology and Inflammation (DPT-II)
- Office of Infectious Diseases (OID)
- Division of Anti-infectives (DAI)
- Division of Antivirals (DAV)
- Division of Pharm/Tox for Infectious Diseases (DPT-ID)
- Office of Neuroscience (ON)
- Division of Anesthesiology, Addiction Medicine, and Pain Medicine (DAAP)
- Division of Neurology I (DN I)
- Division of Neurology II (DN II)
- Division of Pharm/Tox for Neuroscience (DPT-N)
- Division of Psychiatry (DP)
- Office of New Drugs Regulatory Science Research
- Office of Nonprescription Drugs (ONPD)
- Office of Oncologic Diseases (OOD)
- Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine (ORPURM)
- Division of Pediatrics and Maternal Health (DPMH)
- Division of Rare Diseases and Medical Genetics (DRDMG)
- Division of Urology, Obstetrics, and Gynecology (DUOG)
- Division of Pharm/Tox for Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine (DPT-RPRUMI)
- Office of Specialty Medicine (OSM)
- Office of Therapeutic Biologics and Biosimilars (OTBB)
- Clinical Outcome Assessments (COA) Staff
- Labeling Policy Team
- Office of Immunology and Inflammation (OII)
Office of Pharmaceutical Quality (OPQ)
- Office of Policy for Pharmaceutical Quality
- Office of Quality Surveillance
- Office of Pharmaceutical Quality Research
- Office of Quality Assurance
- Office of Program and Regulatory Operations
- Office of Product Quality Assessment I
- Office of Product Quality Assessment II
- Office of Product Quality Assessment III
- Office of Pharmaceutical Manufacturing Assessment
Office of Regulatory Policy
Office of Strategic Programs
Office of Surveillance and Epidemiology
Office of Translational Sciences